ZURICH (Reuters) - Novartis' Ilaris helps reduce patients' symptoms and the frequency of attacks in two rare inflammatory diseases, mid-stage studies showed, as the Swiss drugmaker looks to expand the use of the medicine.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/YEFfAiI0tCc/us-novartis-ilaris-idUSBRE8AA0AD20121111
phlebotomy tech schools phlebotomy training in arizona phlebotomy licensing
No comments:
Post a Comment